Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals

Date: 28-08-2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Listing Department Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai-400051 Mumbai-400001 Scrip Code: MUKKA Scrip Code: 544135 Dear Sir/Madam, Subject: Intimation of receipt of the In-Principal approval from National Stock Exchange of India Limited and BSE Limited for issue of convertible warrants to non-promoter category on a preferential basis. Ref: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI LODR Regulations”), read with the applicable provisions thereof, we hereby inform you that Mukka Proteins Limited (“Company”) has received the In-Principle Approval from National Stock Exchange of India Limited (“NSE”) and BSE Limited (“BSE”) in respect of the proposed issue and allotment of Convertible Warrants to persons belonging to the Non-Promoter Category on a preferential basis, subject to the applicable provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI LODR Regulations and other applicable laws. The details of the In-Principle Approvals received by the Company are as under: Sr. Name of Stock Exchange Reference / Letter No. Date of Approval 1 National Stock Exchange of India NSE/LIST/55764 August 28, 2026 Limited 2 BSE Limited LOD/PREF/DA/FIP/721/2026- August 28, 2026 The aforesaid In-Principle Approvals have been granted in connection with the proposed issue and allotment of Convertible Warrants on a preferential basis to persons belonging to the Non-Promoter Category, in accordance with the terms and conditions stipulated in the respective approval letters and subject to compliance with the applicable statutory and regulatory requirements. Copies of the In-Principle Approval letters issued by NSE and BSE are enclosed herewith for your information and records. The disclosure as required under Schedule III of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 is enclosed as Annexure-1 to this letter. This is for your information and records. Thanking you, For Mukka Proteins Limited, Mehaboobsab Mahmadgous Chalyal Company Secretary & Compliance Officer Membership No.: A67502 Encl: as above. Annexure-1 S. No. Particulars Details 1. Name of the regulatory or licensing National Stock Exchange of India Limited authority (NSE) & BSE Limited (BSE) 2. Brief details of the approval/license In-Principle approval granted by NSE and obtained/ withdrawn/ surrendered BSE for issue and allotment of 2,00,00,000 Convertible Warrants of Re. 1/- each at an issue price of Rs. 23.50/- each to the Non- Promoters on a preferential basis. 3. Impact/relevance of such Upon receipt of the In-Principle approvals, approval/license to the listed entity the Company is permitted to issue and allotment of 2,00,00,000 Convertible Warrants of Re. 1/- each at an issue price of Rs. 23.50/- each to the Non-Promoters on a preferential basis. 4. Withdrawal/cancellation or Not Applicable suspension of license/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any 5. Period for which such As per the relevant applicable provisions approval/license is/was valid 6. The actual impact (monetary or Not Applicable otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval Ref: NSE/LIST/55764 August 28, 2026 The Company Secretary Mukka Proteins Limited Dear Madam, Sub: In - Principle approval under Regulation 28(1) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 We are in receipt of your application regarding In-principle approval for issue of20000000Equity shares of Re. 1/-each pursuant to conversion of Warrants issued on Preferential basis in terms of Regulation 28(1) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. In this regard, the Exchange is pleased to grant in-principle approval for the said issue subject to the Company fulfilling the following conditions: 1. Filing the listing application at the earliest from the date of allotment. 2. Receipt of statutory and other approvals and compliance of guidelines/regulations issued by the statutory authorities including SEBI, RBI, MCA, etc. 3. Compliance with all the applicable guidelines, regulations, directions of the Exchange or any statutory authorities as on the date of listing application. 4. Compliance of all conditions as per the SEBI (LODR) Regulations, 2015 as on date of listing, Companies Act, 1956 / Companies Act, 2013 and other applicable laws. 5. Submissions of documents as may be required by NSE and payment of applicable fees. Further, the company is advised to strengthen internal controls (to monitor trades being executed by the proposed allottees in the scrip of the company) before allotment of securities in order to avoid any non-compliances in respect of trades being executed by the allottees in contravention of provisions of Chapter V of SEBI (ICDR) Regulations. In this regard, a) The Company is advised to obtain an undertaking from the allottee(s) confirming that they shall not do intra-day trading in the scrip of the company or any sale in the scrip of the company till the allotment date of the security as required under SEBI (ICDR) Regulations. b) The Company may note that the responsibility/onus is solely on the Issuer company to verify the above (a) and ensure compliance with applicable provisions including Regulation 167(6) of SEBI ICDR regulations, 2018. c) The Company may also note that any non-compliances, if observed by the exchanges post the undertaking and verification by the Issuer company may impact the listing of such shares. Kindly note, this Exchange letter should not be construed as approval under any other Act /Regulation/rule/bye laws (except as referred above) for which the Company may be required to obtain approval from other department(s) of the Exchange. The Company is requested to separately take up matter with the concerned departments for approval, if any. The Exchange reserves its right to withdraw its in-principle approval at a later stage if the information submitted to the Exchange is found to be incomplete/incorrect/misleading/false or in contravention of any Rules, Bye-laws and Regulations of the Exchange, SEBI (LODR) Regulations, 2015, Guidelines/ Regulations issued by statutory authorities, etc. Yours faithfully, For NationalStockExchange ofIndia Limited Pooja Pashte Manager National Securities Depository Limited Central Depository Services Limited P.S. Checklist of all the further issues is available on website of the exchange at the following URL: https://www.nseindia.com/companies-listing/raising-capital-further-issuesmain-sme-checklist The National Stock Exchange of India (NSE) has announced the launch of NEAPS mobile application.